Oramed Pharmaceuticals Inc (ORMP)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Oramed Pharmaceuticals Inc (ORMP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013560
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oramed Pharmaceuticals Inc (Oramed) engages in the research and development of novel pharmaceutical solutions, comprising an oral insulin capsule for the treatment of individuals with diabetes, and orally ingestible capsules or pills for delivery of other polypeptides. It developed a unique proprietary platform technology, Protein Oral Delivery (POD) to transform injectable treatments into oral therapies. The technology allows for the oral delivery of drugs currently administered only by injection. The company tested its technology through various animal and human studies on its two flagship products, ORMD-0801, an orally ingestible insulin capsule; and ORMD-0901, an oral GLP-1 analog (exenatide) capsule. Oramed is headquartered in Jerusalem, Israel.

Oramed Pharmaceuticals Inc (ORMP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Oramed to Enter into Licensing Agreement with Sinopharm and Hefei Life Science 11
Guangxi Wuzhou Pharma Enters into Licensing Agreement with Oramed Pharma 12
Hefei Tianhui Incubator of Technologies Enters into Licensing Agreement with Oramed Pharma 13
Equity Offering 14
Oramed Pharma to Raise up to USD25 Million in Public Offering of Shares 14
Oramed Pharma Raises USD12 Million in Private Placement of Shares 15
Oramed Pharma Raises USD5.4 Million in Private Placement of Shares 16
Oramed Pharma to Raise USD5.4 Million in Private Placement of Shares 18
Oramed Pharma Completes Private Placement Of Shares For US$15.8 Million 19
Oramed Pharma Completes Private Placement Of Shares For US$4.6 Million 21
Oramed Pharma Withdraws Public Offering Of Common Stock For US$13 Million 22
Oramed Pharma Completes Private Placement Of Units US$5 Million 23
Oramed Pharma Completes Private Placement Of Units For US$3.6 Million 24
Oramed Pharma Completes Private Placement For US$3.36 Million 25
Acquisition 27
Sinopharm and Hefei Life Science to Acquire 10% Stake In Oramed Pharma 27
Guangxi Wuzhou Pharma Acquires Stake in Oramed Pharma for USD5 Million 28
D.N.A Biomedical Completes Acquisition Of 47% JV Stake In Entera Bio From Oramed For US$1 Million 29
Oramed Pharmaceuticals Inc – Key Competitors 30
Oramed Pharmaceuticals Inc – Key Employees 31
Oramed Pharmaceuticals Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Joint Venture 32
Recent Developments 33
Corporate Communications 33
Mar 21, 2017: Oramed Appoints Dr. Ronald Law as Chief Strategy Officer 33
Product News 34
06/21/2016: Oramed Announces $6.5 Million Milestone Payment from HTIT 34
05/02/2017: Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule 35
Clinical Trials 36
Aug 02, 2016: Oramed Receives Additional $4 Million Milestone Payment From HTIT 36
Jul 28, 2016: Oramed Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering of Glucose Levels vs Placebo 37
May 18, 2016: Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study 38
Apr 05, 2016: Oramed Completes Phase IIb Oral Insulin Study 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Oramed Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Oramed to Enter into Licensing Agreement with Sinopharm and Hefei Life Science 11
Guangxi Wuzhou Pharma Enters into Licensing Agreement with Oramed Pharma 12
Hefei Tianhui Incubator of Technologies Enters into Licensing Agreement with Oramed Pharma 13
Oramed Pharma to Raise up to USD25 Million in Public Offering of Shares 14
Oramed Pharma Raises USD12 Million in Private Placement of Shares 15
Oramed Pharma Raises USD5.4 Million in Private Placement of Shares 16
Oramed Pharma to Raise USD5.4 Million in Private Placement of Shares 18
Oramed Pharma Completes Private Placement Of Shares For US$15.8 Million 19
Oramed Pharma Completes Private Placement Of Shares For US$4.6 Million 21
Oramed Pharma Withdraws Public Offering Of Common Stock For US$13 Million 22
Oramed Pharma Completes Private Placement Of Units US$5 Million 23
Oramed Pharma Completes Private Placement Of Units For US$3.6 Million 24
Oramed Pharma Completes Private Placement For US$3.36 Million 25
Sinopharm and Hefei Life Science to Acquire 10% Stake In Oramed Pharma 27
Guangxi Wuzhou Pharma Acquires Stake in Oramed Pharma for USD5 Million 28
D.N.A Biomedical Completes Acquisition Of 47% JV Stake In Entera Bio From Oramed For US$1 Million 29
Oramed Pharmaceuticals Inc, Key Competitors 30
Oramed Pharmaceuticals Inc, Key Employees 31
Oramed Pharmaceuticals Inc, Subsidiaries 32
Oramed Pharmaceuticals Inc, Joint Venture 32

★海外企業調査レポート[Oramed Pharmaceuticals Inc (ORMP)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Slavneft-Megionneftegaz (MFGS):企業の財務・戦略的SWOT分析
    Summary Slavneft-Megionneftegaz (Megionneftegaz), a subsidiary of Slavneft, is an oil and gas company that operates oil fields. The company’s activities include appraisal of oil and gas fields, oil and gas production, and well drilling and operation. Megionneftegaz develops and introduces advanced t …
  • Unity Biotechnology Inc (UBX):製薬・医療:M&Aディール及び事業提携情報
    Summary Unity Biotechnology Inc (Unity Biotechnology), formerly Forge Inc is a biotechnology company that researches, develops and commercializes therapeutics for the treatment of age-related diseases. The company focuses on the development of senolytic medicines to eliminate senescent cells. The co …
  • Geisinger:医療機器:M&Aディール及び事業提携情報
    Summary Geisinger formerly, Geisinger Health System is an integrated health services organization that provides medical and surgical specialties and sub-specialties, and related health services. It offers medical services for patients related to cardiology, ENT, gastroenterology, gynecology, cancer, …
  • Macquarie Telecom Group Limited (MAQ):企業の財務・戦略的SWOT分析
    Macquarie Telecom Group Limited (MAQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Aevi Genomic Medicine Inc (GNMX)-製薬・医療分野:企業M&A・提携分析
    Summary Aevi Genomic Medicine Inc (Aevi), formerly Medgenics Inc is a research and development company that discovers and develops novel therapies for pediatric onset and life-altering diseases.The company’s pipeline products include AEVI-001 and AEVI-002. Its lead product AEVI-001, is a glutamaterg …
  • Transfield Holdings Pty Ltd:企業の戦略的SWOT分析
    Transfield Holdings Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • NV Energy Inc:電力:M&Aディール及び事業提携情報
    Summary NV Energy Inc (NVE) is an energy holding company, which provides a wide range of services through its principal subsidiaries, Nevada Power Co and Sierra Pacific Power Co. NVE delivers electricity to residential, commercial and industrial customers. It also sells electricity and natural gas t …
  • Jordan Trade Facilities Company PLC (JOTF):企業の財務・戦略的SWOT分析
    Jordan Trade Facilities Company PLC (JOTF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Enbridge Inc (ENB):企業の財務・戦略的SWOT分析
    Enbridge Inc (ENB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • CompuGroup Medical Deutschland AG (COP)-医療機器分野:企業M&A・提携分析
    Summary CompuGroup Medical Deutschland AG (CGM) is a provider of medical software products and healthcare services. The company's products comprise communication solutions, software assisted medicine, dentist information systems, ambulatory information systems, drug safety, patient marketing, and ot …
  • Ebiquity plc (EBQ):企業の財務・戦略的SWOT分析
    Summary Ebiquity plc (Ebiquity) is a marketing and media consultancy service provider. The company offers services such as marketing performance optimization services, media value measurement and market intelligence. Its business areas comprise data analytics and advanced analytics. Ebiquity’s data …
  • Bracco Imaging SpA-医療機器分野:企業M&A・提携分析
    Summary Bracco Imaging SpA (Bracco), a subsidiary of Bracco SpA is a provider of diagnostic imaging solutions. The company offers diagnostic imaging, bracco pharma and health services. It offers solutions which include X-Ray, CT colonography, magnetic resonance imaging, diagnostic radiology, endosco …
  • Chromatin Inc:企業のM&A・事業提携・投資動向
    Chromatin Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Chromatin Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • The Dow Chemical Co (DOW)-石油・ガス分野:企業M&A・提携分析
    Summary The Dow Chemical Company (Dow) is a diversified chemical company. Its businesses encompass specialty chemicals, advanced materials, agrosciences and plastics. The company manufactures and supplies products used primarily as raw materials in the manufacture of customer products and services. …
  • Suncor Energy Inc (SU):電力:M&Aディール及び事業提携情報
    Summary Suncor Energy Inc. (Suncor) is an integrated energy company that mainly focuses on the development of Athabasca oil sands. It carries out development and up gradation of oil sands; offshore and onshore oil and gas production; refining of crude oil and marketing of petroleum and petrochemical …
  • Sanwa Kagaku Kenkyusho Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Sanwa Kagaku Kenkyusho Co Ltd (Sanwa), a subsidiary of Suzuken Co Ltd is a contract manufacturing company that conducts research, manufactures and commercializes of pharmaceutical drugs for treating diagnostics, healthcare products, and medical and nursing care nutritionals. The company also …
  • Aiphone Co Ltd (6718):企業の財務・戦略的SWOT分析
    Aiphone Co Ltd (6718) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Solaris Oilfield Infrastructure Inc (SOI):石油・ガス:M&Aディール及び事業提携情報
    Summary Solaris Oilfield Infrastructure Inc (Solaris) is a provider of supply chain management and logistics solutions for oil and natural gas industry. The company manufactures and provides mobile proppant management systems that unload, store and deliver proppant at oil and natural gas well sites …
  • Mercer International Inc (MERC):企業の財務・戦略的SWOT分析
    Mercer International Inc (MERC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • SCB Life Assurance Public Company Limited:戦略・SWOT・企業財務分析
    SCB Life Assurance Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary SCB Life Assurance Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆